Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Summary
A large trial in the UK tested a new blood test called Galleri, designed to detect more than 50 types of cancer early. The study found that the test did not lower the number of advanced-stage cancer diagnoses compared to normal screening methods.Key Facts
- The trial involved 142,942 NHS patients aged 50 to 77 without cancer symptoms.
- Participants gave blood samples once a year for three years, with half tested using the Galleri multi-cancer detection test.
- The main goal was to see if the test reduced late-stage (stage 3 and 4) cancer diagnoses.
- The trial did not meet this main goal, showing no significant reduction in advanced cancers with the Galleri test.
- There was a 14% drop in the most advanced stage 4 cancers in the Galleri group, which some researchers found encouraging.
- Experts caution that these results do not fully support widespread use of the test yet.
- More data on cancer deaths will come in a few years to better understand the test’s impact.
- Galleri is developed by Grail, a California-based company focused on early cancer detection technologies.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.